

The Role of Clinicians in Supporting Smoking Cessation for Individuals with Cardiovascular Disease and Mental Illness

Dr Angela Difeng Wu
Oxford Tobacco Addiction Group
Centre of Evidence-Based Medicine
University of Oxford

Wednesday, 07 January 2026

Disclosures

Research Funding Source: British Heart Foundation

Presenter: No conflicts to declare and no tobacco-related funding sources over the last 10 years for any research

My Journey into Tobacco Research



What does 'choice' mean when it comes to health?



Cardiovascular disease (CVD) causes 31% of deaths worldwide (1)

17% of people in Europe are living with CVD (2).

Tobacco is a key risk factor—and quitting can prevent both first-time and repeat cardiac events (3-4).

8000 people with CVD event

26% were
smoking at
diagnosis

Six months
later 61%
still
smoking

Majority
prescribed
ACE
inhibitors,
statins and
beta-
blockers

19%
advised to
attend a
stop
smoking
clinic

20% of
those who
attended
were
offered
medication

1 in 8 people live with mental illness in the world (6).

People with serious mental illness die 15–20 years younger, mostly from preventable physical illnesses (7).

Smoking is the leading contributor for these preventable physical illnesses (8).

Inequalities?

UK general smoking rate: 46% (1970s) → 12.9% (2022) (9).

Smoking rates have not decreased for people living with mental illness in UK(10).

Up to 85% of people with schizophrenia smoke (11).

Many use smoking to cope with stress with ~40% believe it relieves stress (12,13).

Common in both psychiatric and general populations (14,15).

Fear of mental health decline deters quitting and clinicians may hesitate to recommend smoking cessation (16,17).

BUT quitting associated with improved mental health (18,19).



Cardiovascular Disease



Mental Illness



Smoking cessation as an
intervention

PhD Aims and Project Breakdown

Extent and Rate of Harm
& Secondary Data Analysis

Smoking Cessation Treatments
Offered and Effectiveness

Motivating Physicians to
Intervene

Smoking cessation for secondary prevention of cardiovascular disease, a systematic review



Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

[Intervention Review]

Smoking cessation for secondary prevention of cardiovascular disease

Angela Difeng Wu¹, Nicola Lindson¹, Jamie Hartmann-Boyce¹, Azizia Wahedi², Anisa Hajizadeh¹, Annika Theodoulou¹, Elizabeth T Thomas¹, Charlotte Lee¹, Paul Aveyard¹

Risk Reduction for secondary CVD events →

Authors' conclusions

Implications for practice

- People with heart disease who smoke, and their clinicians, can be reassured that stopping smoking is associated with a decreased risk of secondary cardiovascular disease (CVD) outcomes, including CVD, major adverse cardiovascular events (MACE), all-cause mortality, non-fatal myocardial infarction, non-fatal stroke and new-onset angina.
- People with heart disease who smoke, and their clinicians, can be reassured that smoking cessation will not worsen, and may improve quality of life.

Implications for research

- Further studies that examine the impact of smoking cessation while controlling for secondary CVD prevention medication and severity of initial coronary heart disease (CHD) event, as well as other listed confounding factors, would strengthen the evidence on the impact of smoking cessation.
- Research investigating the severity of the initial CHD event, as well as intensity of smoking prior to cessation, may strengthen the evidence on magnitude and speed of smoking cessation impact.
- Studies should also consider investigating the impact of combined benefit of smoking cessation and secondary prevention medication.
- Future studies should also stratify results by sex, where feasible, as the majority of studies in this review were predominately focused on men.
- Additional, larger studies that examine the impact of smoking cessation on CVD would also strengthen the evidence as the smaller studies included in the review may be exaggerating the benefits of cessation.
- A systematic review of intervention studies supporting smoking cessation in people with established cardiac disease would strengthen the evidence of causality. Individual trials are likely to be too small to show benefits, but pooling can improve statistical power to reveal the health impact.

Smoking cessation for mental health, secondary data analysis of randomised control trial

JAMA
Network | **Open**™

Original Investigation | Psychiatry

Smoking Cessation and Changes in Anxiety and Depression in Adults With and Without Psychiatric Disorders

Angela Difeng Wu, MSc; Min Gao, PhD; Paul Aveyard, PhD; Gemma Taylor, PhD

Results and Implications

Table 2. Hospital Anxiety and Depression Scale Scores for Participants by Smoking Status and Unadjusted Complete Case Tobit Regression

Outcome and time	Score, mean (SD)
Anxiety ^a	
Continued smoking	
Baseline	4.31 (3.67)
Follow-up	2.29 (3.43)
Stopped smoking	
Baseline	3.81 (3.43)
Follow-up	1.51 (2.79)
Depression ^b	
Continued smoking	
Baseline	2.51 (2.92)
Follow-up	1.67 (2.77)
Stopped smoking	
Baseline	2.21 (2.81)
Follow-up	0.92 (2.10)

^a $\beta = -0.28$ (95% CI, -0.41 to -0.14).

^b $\beta = -0.29$ (95% CI, -0.4 to -0.19).

Table 3. Change in Hospital Depression and Anxiety Scale Scores for People Who Remained Abstinent Between Weeks 9 and 24

Outcome	β (95% CI)
Depression	
Tobit complete adjusted	-0.47 (-0.61 to -0.33)
PSM Tobit adjusted	-0.42 (-0.6 to -0.24)
Tobit removal of bupropion	-0.37 (-0.53 to -0.21)
Tobit without psychiatric history	-0.32 (-0.48 to -0.15)
Tobit with psychiatric history	-0.60 (-0.82 to -0.38)
Multiple imputation Tobit	-0.97 (-1.15 to -0.78)
Multiple imputation PSM	-0.53 (-0.67 to -0.4)
Anxiety	
Tobit complete adjusted	-0.40 (-0.58 to -0.22)
PSM Tobit adjusted	-0.32 (-0.53 to -0.11)
Tobit removal of bupropion	-0.33 (-0.53 to -0.12)
Tobit without psychiatric history	-0.29 (-0.50 to -0.80)
Tobit with psychiatric history	-0.48 (-0.76 to -0.20)
Multiple imputation Tobit	-0.33 (-0.53 to -0.12)
Multiple imputation PSM	-0.54 (-0.7 to -0.37)

Abbreviation: PSM, propensity score matching.

Why Focus on Smoking Cessation in CVD and Mental Illness?



Initial studies **highlighted smoking cessation as a key intervention to improve outcomes for people with cardiovascular disease (CVD) and mental illness**



These findings led to **two PhD projects exploring:**

What is currently being offered by **GPs** for smoking cessation

How we can incentivise more effective interventions in practice

The Role of Financial Incentives (Quality of Outcomes Framework)

- GPs are incentivised to:
 - Record smoking status
 - Provide advice/support
- System rewards advice to quit the same as providing treatment
 - despite differences in effectiveness (20).
- Overuse of advice codes; underuse of effective interventions in general population with minimal change in smoking abstinence rates (21).

Objectives and Methods

- Measure frequency/types of cessation support in heart disease patients
- Compare support and success rates in patients with vs. without mental illness
- Source: Electronic GP records
- Participants: Adults with incident heart disease (1996–2019)



Categorised Interventions: Smoking services referral

Brief intervention


Education or advice

Medication


Counselling



Before Incentive
N=57,211



After Incentive
N=101,259



■ Education ■ Pharmacological ■ Referral ■ Brief ■ Counselling ■ No intervention

Smoking Cessation Intervention on Likelihood of Abstinence	Odds Ratio (OR)	95% Confidence Interval (CI)
Education	1.31	1.27 1.34
Prescription	0.66	0.61 0.71
Referral	0.45	0.42 0.49
Brief	0.49	0.40 0.60
Counselling	0.65	0.46 0.92
Merged Interventions	1.41	1.36 1.45

	OR	95% CI	Reference Group
Likelihood of Smoking Intervention Record			No Mental Illness
Common Mental Illness (CMI)	1.08	1.04, 1.13	
Serious Mental Illness (SMI)	1.07	0.96, 1.20	
Likelihood of Abstinence with Intervention Record			
CMI	0.74	0.71, 0.77	
SMI	0.51	0.44, 0.57	
Likelihood of Abstinence with Intervention Record			
Before Financial Incentive	5.09	4.84, 5.35	After Incentive

Investigating the association between recorded smoking cessation interventions and smoking cessation in people living with cardiovascular disease using UK general practice data

Research | [Open access](#) | Published: 01 May 2025

Volume 26, article number 141, (2025) | [Cite this article](#)

People who receive intervention are more likely to quit HOWEVER most widely used intervention is least effective for smoking cessation

System-level incentives like QOF may need reform to reward quality, not just presence of “support”

Doctor Attitude towards Smoking

- UK guidance frames smoking as a dependency needing treatment (22).
- Beliefs about patient responsibility affect likelihood to offer support (23).
- Clinicians less likely to intervene if they feel the patient is “choosing” to smoke (24).

People must take more responsibility for their own health, says health secretary Matt Hancock



Agency Awareness

(6,7)

Research Question

Does responsibility framing influence a GP's likelihood of offering evidence-based cessation support?

What attitudes do UK doctors have regarding smoking and health?

Participants:

GPs, students, doctors

Setting:

Between-subjects online study

Exposure:

Responsibility-framed scenarios

Primary
Outcomes:

Intention, duty, desire to help

Frames

Control Condition

OxPrimaryCareSci
 @OxPrimaryCare

Newest research reaffirms that the most effective way to help people #stopsmoking is through behavioural support and/or medication. GPs should give all patients smoking cessation support.
 Learn more: <http://bit.ly/3YqvbpA>



4:03 PM · Mar 9, 2023


2 Retweets 1 Quote Tweet 4 Likes

Reply Share Like Save

Shared Responsibility

OxPrimaryCareSci
 @OxPrimaryCare

Newest research reaffirms that the most effective way to help people #stopsmoking is through behavioural support and/or medication. GPs should remind patients they need not quit on their own and offer patients smoking cessation support.
 Learn more: <http://bit.ly/3YqvbpA>



4:03 PM · Mar 9, 2023


2 Retweets 1 Quote Tweet 4 Likes

Reply Share Like Save

Professional Obligation

OxPrimaryCareSci
 @OxPrimaryCare

Newest research reaffirms that the most effective way to help people #stopsmoking is through behavioural support and/or medication. GP failure to provide a patient with smoking cessation support is a failure to meet professional obligations.
 Learn more: <http://bit.ly/3YqvbpA>



4:03 PM · Mar 9, 2023

2 Retweets 1 Quote Tweet 4 Likes


Reply Share Like Save

Scenarios


Context of Illness		Context of Consultation	
Cardiovascular Disease		Computer record	
Serious Mental Illness		Time constraints	
Non-smoking illness- sprained ankle		Patient previous mention of no motivation to quit	

Your patient, Sandy, has come in to see you about a sprained ankle. You are confident that they will recover swiftly. Their records indicate that when they last visited the clinic they smoked cigarettes.

	Strongly disagree	Somewhat disagree	Neither agree nor disagree	Somewhat agree	Strongly agree
I ought to offer this patient smoking cessation support	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
I want to offer this patient smoking cessation support	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
I intend to offer this patient smoking cessation support	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>



Sample population




Multivariable Linear Regression

Framing had no effect on:

- *Desire* to offer support
- *Duty* to offer support

Professional obligation frame associated with
↑ intention to offer support

Attitude Statements



Implications





Oxford Tobacco Addiction Group (OXTAG)

Our group produces primary research and systematic reviews of the evidence on interventions to prevent and treat tobacco addiction. This includes interventions for smoking cessation, for preventing smoking uptake, and public policy interventions for reducing smoking prevalence.

WHO WE ARE

We are a group of researchers and doctoral students based within the **Centre for Evidence-Based Medicine** and the **Interdisciplinary Research in Health Sciences** team at the **Nuffield Department of Primary Care Health Sciences**, chaired by **Dr Nicola Lindson**. We work together to produce research that reduces the burden of tobacco use and smoking-related disease.

Nicola Lindson
Associate Professor



Annika Theodoulou
Systematic Reviewer & Doctoral researcher



Jonathan Livingstone-Banks
Lecturer & Senior Researcher in Evidence-Based Healthcare



Rachna Begh
Deputy Course Director, MSc Translational Health Sciences & University Research Lecturer



Anne Ferrey
Senior Researcher and Course Director, MSc Translational Health Sciences



Ailsa Butler
Postdoctoral Researcher & Systematic Reviewer



Andrea Leinberger-Jabari
DPhil Candidate



Monserrat Guilherme Conde
Researcher



Angela Wu
Postdoctoral Researcher & Mental Health First Aider



Xinxin Yang
Post-doctoral Researcher



Jack Joyce
Research Programme Manager



Ethan Knight
Research Assistant



Any Questions?



References

1. Kendir C, Van Den Akker M, Vos R, Metsemakers J. Cardiovascular disease patients have increased risk for comorbidity: A cross-sectional study in the Netherlands. *European Journal of General Practice.* 2018;24(1):45-50.
2. Wilkins E, Wilson L, Wickramasinghe K, Bhatnagar P, Leal J, Luengo-Fernandez R, et al. European Cardiovascular Disease Statistics 2017. Brussels: European Heart Network; 2017.
3. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. *Cochrane Database Syst Rev.* 2003(4):CD003041.
4. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease - A systematic review. *Jama-Journal of the American Medical Association.* 2003;290(1):86-97.
5. Kotseva K, Wood D, De Bacquer D, De Backer G, Ryden L, Jennings C, et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. *Eur J Prev Cardiol.* 2016;23(6):636-48.
6. WHO. Mental Health 2022 [Available from: <https://www.who.int/news-room/fact-sheets/detail/mental-health-strengthening-our-response>].
7. The Mental Health Task F. The Five Year Forward View For Mental Health. URL: <https://www.england.nhs.uk/wp-content/uploads/2016/02/Mental-Health-Taskforce-FYFV-final.pdf>. Accessed: 06/06/2022. Contract No.: Report.
8. Smoking and mental health. In: Physicians RCo, editor. 2013.
9. (ONS) OfNS. Adult smoking habits in the UK: 2022 2023 [released 5 September 2023; Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/bulletins/adultsmokinghabitsinengland/2022>].
10. Brose LS, Brown J, Robson D, McNeill A. Mental health, smoking, harm reduction and quit attempts – a population survey in England. *BMC Public Health.* 2020;20(1):1237.
11. Heffner JL, Strawh JR, DelBello MP, Strakowski SM, Anthenelli RM. The co-occurrence of cigarette smoking and bipolar disorder: phenomenology and treatment considerations. *Bipolar Disord.* 2011;13(5-6):439-53.
12. Hughes JR. Effects of abstinence from tobacco: valid symptoms and time course. *Nicotine Tob Res.* 2007;9(3):315-27.
13. Perski O, Theodoraki M, Cox S, Kock L, Shahab L, Brown J. Associations between smoking to relieve stress, motivation to stop and quit attempts across the social spectrum: A population survey in England. *PLOS ONE.* 2022;17(5):e0268447.
14. Kerr S, Watson H, Tolson D, Lough M, Brown M. Smoking after the age of 65 years: a qualitative exploration of older current and former smokers' views on smoking, stopping smoking, and smoking cessation resources and services. *Health & Social Care in the Community.* 2006;14(6):572-82.
15. Clancy N, Zwar N, Richmond R. Depression, smoking and smoking cessation: a qualitative study. *Family Practice.* 2013;30(5):587-92.
16. McNally L, Oyefeso A, Annan J, Perryman K, Bloor R, Freeman S, et al. A survey of staff attitudes to smoking-related policy and intervention in psychiatric and general health care settings. *2006;28(3):192-6.*
17. Johnson JL, Moffat BM, Malchy LA. In the shadow of a new smoke free policy: A discourse analysis of health care providers' engagement in tobacco control in community mental health. *International Journal of Mental Health Systems.* 2010;4(1):23.
18. Taylor G, McNeill A, Girling A, Farley A, Lindson-Hawley N, Aveyard P. Change in mental health after smoking cessation: systematic review and meta-analysis. *BMJ.* 2014;348:g1151.
19. Taylor GM, Lindson N, Farley A, Leinberger-Jabari A, Sawyer K, Te Water Naude R, et al. Smoking cessation for improving mental health. *Cochrane Database Syst Rev.* 2021;3:CD013522.
20. Aveyard P, Begh R, Parsons A, West R. Brief opportunistic smoking cessation interventions: a systematic review and meta-analysis to compare advice to quit and offer of assistance. *Addiction.* 2012;107(6):1066-73.
21. Szatkowski L, Aveyard P. Provision of smoking cessation support in UK primary care: impact of the 2012 QOF revision. *British Journal of General Practice.* 2016;66(642):e10-e5.
22. OHID. Smoking and tobacco: applying All Our Health. In: Disparities OfHIA, editor. 2022.
23. van Eerd EAM, Bech Risør M, Spigt M, Godycki-Cwirko M, Andreeva E, Francis N, et al. Why do physicians lack engagement with smoking cessation treatment in their COPD patients? A multinational qualitative study. *NPJ Prim Care Respir Med.* 2017;27(1):41.
24. Meijer E, Chavannes NH. Lacking willpower? A latent class analysis of healthcare providers' perceptions of smokers' responsibility for smoking. *Patient Education and Counseling.* 2021;104(3):620-6.
25. Kahneman D, Tversky A. The psychology of preferences. *Science.* 1982 // 1982;246